Adjuvant Radiotherapy for Patients with Locally Advanced Prostate Cancer-A New Standard?

European Urology

Volumn 54, Issue 3, 2008, Pages 528-542

  Ganswindt, Ute ^a   Stenzl, Arnulf ^b   Bamberg, Michael ^b   Belka, Claus ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Adjuvant radiotherapy; Locally advanced prostate cancer; Prostatic neoplasm; Radical prostatectomy; Randomised trial

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ABDOMINAL PAIN; ADJUVANT RADIOTHERAPY; ADJUVANT THERAPY; BLADDER; BLADDER SPASM; CANCER RISK; COLIC; DIARRHEA; DIGESTIVE SYSTEM FISTULA; DIGESTIVE SYSTEM PERFORATION; DISEASE FREE SURVIVAL; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TRACT; HEMATURIA; HORMONAL THERAPY; HUMAN; INFORMATION RETRIEVAL; INTESTINE FUNCTION; NOCTURIA; PATIENT SELECTION; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SALVAGE THERAPY; TELANGIECTASIA; TOXICITY; URETER; UROGENITAL SYSTEM;

EID: 47949104524     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.06.059     Document Type: Review

References (58)

1. Zincke H., Bergstralh E.J., Blute M.L., Myers R.P., Barrett D.M., and Lieber M.M. Radical prostatectomy for clinically localized prostate cancer: long-term results of 1143 patients from a single institution. J Clin Oncol 12 (1994) 2254-2263
2. Kupelian P., Katcher J., Levin H., Zippe C., and Klein E. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology 48 (1996) 249-260
3. Moul J.W., Connelly R.R., Lubeck D.P., Bauer J.J., Sun L., and Flanders S.C. Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases. J Urol 166 (2001) 1322-1327
4. Roehl K.A., Han M., Ramos C.G., Antenor J.A., and Catalona W.J. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3478 consecutive patients: long-term results. J Urol 172 (2004) 910-914
5. Partin A.W., Mangold L.A., Lamm D.M., Walsh P.C., Epstein J.I., and Pearson J.D. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 58 (2001) 843-848
6. Kattan M.W., Zelefsky M.J., Kupelian P.A., Scardino P.T., Fuks Z., and Leibel S.A. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 18 (2000) 3352-3359
7. Ward J.F., Zincke H., Bergstralh E.J., Slezak J.M., Myers R.P., and Blute M.L. The impact of surgical approach (nerve bundle preservation versus wide local excision) on surgical margins and biochemical recurrence following radical prostatectomy. J Urol 172 (2004) 1328-1332
8. Bott S.R., Freeman A.A., Stenning S., Cohen J., and Parkinson M.C. Radical prostatectomy: pathology findings in 1001 cases compared with other major series and over time. BJU Int 95 (2005) 34-39
9. Ward J.F., Slezak J.M., Blute M.L., Bergstralh E.J., and Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-yr outcome. BJU Int 95 (2005) 751-756
10. Schild S.E., Wong W.W., Grado G.L., et al. The result of radical retropubic prostatectomy and adjuvant therapy for pathologic stage C prostate cancer. Int J Radiat Oncol Biol Phys 34 (1996) 535-541
11. Petrovich Z., Lieskovsky G., Langholz B., Huberman M., Streeter O., and Skinner D.G. Nonrandomized comparison of surgery with and without adjuvant pelvic irradiation for patients with pT3N0 adenocarcinoma of the prostate. Am J Clin Oncol 24 (2001) 537-546
12. Hawkins C.A., Bergstralh E.J., Lieber M.M., and Zincke H. Influence of DNA ploidy and adjuvant treatment on progression and survival in patients with pathologic stage T3 (PT3) prostate cancer after radical retropubic prostatectomy. Urology 46 (1995) 356-364
13. Anscher M.S., Robertson C.N., and Prosnitz R. Adjuvant radiotherapy for pathologic stage T3/T4 adenocarcinoma of the prostate: ten-year update. Int J Radiat Oncol Biol Phys 33 (1995) 37-43
14. Leibovich B.C., Engen D.E., Patterson D.E., et al. Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin. J Urol 163 (2000) 1178-1182
15. Cozzarini C., Bolognesi A., Ceresoli G.L., et al. Role of postoperative radiotherapy after pelvic lymphadenectomy and radical retropubic prostatectomy: a single institute experience of 415 patients. Int J Radiat Oncol Biol Phys 59 (2004) 674-683
16. Vargas C., Kestin L.L., Weed D.W., Krauss D., Vicini F.A., and Martinez A.A. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features. Int J Radiat Oncol Biol Phys 61 (2005) 714-724
17. Syndikus I., Pickles T., Kostashuk E., and Sullivan L.D. Postoperative radiotherapy for stage pT3 carcinoma of the prostate: improved local control. J Urol 155 (1996) 1983-1986
18. Valicenti R.K., Gomella L.G., Ismail M., et al. The efficacy of early adjuvant radiation therapy for pT3N0 prostate cancer: a matched-pair analysis. Int J Radiat Oncol Biol Phys 45 (1999) 53-58
19. Choo R., Hruby G., Hong J., et al. Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not?. Int J Radiat Oncol Biol Phys 52 (2002) 674-680
20. Collette L., van Poppel H., Bolla M., et al. Patients at high risk of progression after radical prostatectomy: do they all benefit from immediate post-operative irradiation? (EORTC trial 22911). Eur J Cancer 41 (2005) 2662-2672
21. Van der Kwast T.H., Bolla M., van Poppel H., et al. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 25 (2007) 4178-4186
22. Bolla M., van Poppel H., Collette L., et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366 (2005) 572-578
23. Thompson Jr. I.M., Tangen C.M., Paradelo J., et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 296 (2006) 2329-2335
24. Swanson G.P., Hussey M.A., Tangen C.M., et al. Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol 25 (2007) 2225-2229
25. Wiegel T, Bottke D, Willich N, et al. Phase III results of adjuvant radiotherapy (RT) versus "wait and see" (WS) in patients with pT3 prostate cancer following radical prostatectomy (RP) (ARO 96-02 AUO AP 09/95). J Clin Oncol, ASCO Ann Meeting Proc 2005; 23(Suppl I): 4513.
26. Wiegel T., Bottke D., Willich N., et al. Phase III results of adjuvant radiotherapy versus "wait and see" in patients with pT3 prostate cancer following radical prostatectomy (ARO 96-02/AUO AP 09/95). Int J Radiat Oncol Biol Phys 69 (2007) 172-173
27. Van der Kwast T.H., Collette L., van Poppel H., et al. Impact of pathology review of stage and margin status of radical prostatectomy specimens (EORTC trial 22911). Virchows Arch 449 (2006) 428-434
28. Wiegel T., Bottke D., Willich N., et al. Phase III results of adjuvant radiotherapy (RT) versus wait-and-see (WS) in patients with pT3 prostate cancer following radical prostatectomy (RP) (ARO 96-02/AUO AP 09/95). J Clin Oncol 25 (2007) 5060
29. Lowe B.A., and Lieberman S.F. Disease recurrence and progression in untreated pathologic stage T3 prostate cancer: selecting the patient for adjuvant therapy. J Urol 158 (1997) 1452-1456
30. Epstein J.I., Carmichael M.J., Pizov G., and Walsh P.C. Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term follow-up. J Urol 150 (1993) 135-141
31. Epstein J.I., Pound C.R., Partin A.W., and Walsh P.C. Disease progression following radical prostatectomy in men with Gleason score 7 tumor. J Urol 160 (1998) 97-101
32. D'Amico A.V., Whittington R., Malkowicz S.B., et al. The combination of preoperative prostate specific antigen and postoperative pathological findings to predict prostate specific antigen outcome in clinically localized prostate cancer. J Urol 160 (1998) 2096-2101
33. Zietman A.L., Edelstein R.A., Coen J.J., Babayan R.K., and Krane R.J. Radical prostatectomy for adenocarcinoma of the prostate: the influence of preoperative and pathologic findings on biochemical disease-free outcome. Urology 43 (1994) 828-833
34. Grossfeld G.D., Chang J.J., Broering J.M., et al. Impact of positive surgical margins on prostate cancer recurrence and the use of secondary cancer treatment: data from the CaPSURE database. J Urol 163 (2000) 1171-1177 quiz 1295
35. Han M., Pound C.R., Potter S.R., Partin A.W., Epstein J.I., and Walsh P.C. Isolated local recurrence is rare after radical prostatectomy in men with Gleason 7 prostate cancer and positive surgical margins: therapeutic implications. J Urol 165 (2001) 864-866
36. Grossfeld G.D., Tigrani V.S., Nudell D., et al. Management of a positive surgical margin after radical prostatectomy: decision analysis. J Urol 164 (2000) 93-100
37. Valicenti R.K., Chervoneva I., and Gomella L.G. Importance of margin extent as a predictor of outcome after adjuvant radiotherapy for Gleason score 7 pT3N0 prostate cancer. Int J Radiat Oncol Biol Phys 58 (2004) 1093-1097
38. D'Amico A.V., Whittington R., Malkowicz S.B., et al. An analysis of the time course of postoperative prostate-specific antigen failure in patients with positive surgical margins: implications on the use of adjuvant therapy. Urology 47 (1996) 538-547
39. Epstein J.I., Pizov G., and Walsh P.C. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 71 (1993) 3582-3593
40. Valicenti R.K., Hanlon A.L., Pisansky T.M., et al. A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3/4N0 prostate cancer. Int J Radiat Oncol Biol Phys 63 (2005) S123
41. Katz M.S., Zelefsky M.J., Venkatraman E.S., Fuks Z., Hummer A., and Leibel S.A. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol 21 (2003) 483-489
42. Leventis A.K., Shariat S.F., Kattan M.W., Butler E.B., Wheeler T.M., and Slawin K.M. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol 19 (2001) 1030-1039
43. Stephenson A.J., Shariat S.F., Zelefsky M.J., et al. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA 291 (2004) 1325-1332
44. Stephenson A.J., Slawin K.M., Bianco Jr. F.J., and Scardino P.T. Perspectives on the natural history of recurrent prostate cancer after radical prostatectomy, based on the response to salvage radiotherapy. BJU Int 94 (2004) 1210-1212
45. Coen J.J., Zietman A.L., Thakral H., and Shipley W.U. Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. J Clin Oncol 20 (2002) 3199-3205
46. Keating N.L., O'Malley A.J., and Smith M.R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24 (2006) 4448-4456
47. Shahinian V.B., Kuo Y.F., Freeman J.L., and Goodwin J.S. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352 (2005) 154-164
48. Ganswindt U., Paulsen F., Anastasiadis A.G., Stenzl A., Bamberg M., and Belka C. 70 Gy or more: which dose for which prostate cancer?. J Cancer Res Clin Oncol 131 (2005) 407-419
49. Valicenti R.K., Gomella L.G., Ismail M., Mulholland S.G., Petersen R.O., and Corn B.W. Effect of higher radiation dose on biochemical control after radical prostatectomy for PT3N0 prostate cancer. Int J Radiat Oncol Biol Phys 42 (1998) 501-506
50. Anscher M.S., Clough R., and Dodge R. Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: the first 10 yr. Int J Radiat Oncol Biol Phys 48 (2000) 369-375
51. King C.R., and Spiotto M.T. Improved outcomes with higher doses for salvage radiotherapy after prostatectomy. Int J Radiat Oncol Biol Phys 71 (2008) 23-27
52. Pilepich M.V., Caplan R., Byhardt R.W., et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 15 (1997) 1013-1021
53. Hanks G.E., Pajak T.F., Porter A., et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 21 (2003) 3972-3978
54. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360 (2002) 103-106
55. Lawton C.A., Winter K., Murray K., et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 49 (2001) 937-946
56. Pilepich M.V., Winter K., John M.J., et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50 (2001) 1243-1252
57. Mongiat-Artus P. Words of wisdom. Re: Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. Eur Urol 53 (2008) 448-449
58. Jendrossek V, Henkel M, Hennenlotter J, et al. Analysis of complex PKB/Akt signalling pathways in human prostate cancer samples. BJU Int. In press. Article published online 12 May 2008.